Translational Research
Volume 156, Issue 2 , Pages 53-54 , August 2010

More pieces to the iron chelation puzzle

References 

  1. Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB. Mechanisms for the shuttling of plasma nontransferrin-bound (NTBI) onto deferoxamine by deferiprone. Trans Res. 2010;156:55–67
  2. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001;128:130–138
  3. Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferipron-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009;145:245–254
  4. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–1193
  5. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107:3733–3737
  6. Galanello R. Deferiprone in the treatment of trusnfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag. 2007;3:795–805
  7. Abdelrizak N. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience. Hematol. 2007;12:577–585
  8. Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica. 2005;90:1309–1314
  9. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–1884
  10. Kontoghiorghes GJ. A new era in iron chleation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin. 2009;33:332–338
  11. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93:741–752
  12. Neufeld EJ. Oral chelators deferasirox and deriprone for transfusional iron overload in thatlassemia major: new data, new questions. Blood. 2006;107:3436–3441

PII: S1931-5244(10)00121-0

doi: 10.1016/j.trsl.2010.06.006

Translational Research
Volume 156, Issue 2 , Pages 53-54 , August 2010

Article Tools